PTEN and cancer: In this study, cellular assays which measured key cancer hallmarks such as cellular proliferation, resistance to apoptosis, migratory capacity, and cytoskeletal remodeling were performed to assess the ability of the novel PTEN mutations Q171R and Y65S to confer an oncogenic cellular phenotype.